# OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

> **NCT03698227** · PHASE2 · TERMINATED · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 2 (actual)

## Conditions studied

- Advanced Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Dexrazoxane
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT03698227
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-12
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-06-25
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of efficacy on olaratumab
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698227, "OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03698227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*